Tirzepatide is the active ingredient used in Mounjaro. It is manufactured by Eli Lilly and Co. and is one of the leading brands currently used for type 2 diabetes treatment.
Mounjaro and other GLP-1 RA medications are currently consolitated in MDL 3094. Claimants allege that Eli Lilly and Novo Nordisk failed to inform users of the severe health conditions caused by these medications, such as paralysis of the stomach and NAION.
If you’ve been diagnosed with gastroparesis, vision loss, or bowel obstruction after using Mounjaro or Zepbound, you might be eligible for a claim. Our team at Atraxia Law can assess your case’s eligibility. Please prepare your medical records as proof of your injuries, and our experts will handle the rest.